CD274 and non-small cell lung carcinoma: Therefore, we conducted the meta-analysis of RCTs on PD-1 and PD-L1 inhibitors to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with chemotherapy for the first-line treatment of advanced, metastatic NSCLC.